Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.
Vulvovaginal Candidiasis, Vaginal Yeast Infections
About this trial
This is an interventional treatment trial for Vulvovaginal Candidiasis
Eligibility Criteria
Inclusion Criteria: Healthy, nonpregnant female participants aged ≥18 years with a clinical diagnosis of symptomatic acute VVC. Positive baseline potassium hydroxide (KOH) wet mount from a vaginal smear revealing filamentous hyphae/pseudohyphae or budding yeast cells. Presence of ≥1 vulvovaginal sign. Presence of ≥1 vulvovaginal symptom. Composite Candida severity score of ≥4. Exclusion Criteria: Abnormal Papanicolaou smear in the preceding 12 months. Patients who had oral or intravenous antifungal agents within 4 weeks, or used topical vaginal antifungal drugs within 1 week before the study. Known human immunodeficiency virus infection, Liver disease or abnormal liver function tests, lactation, pregnancy, and allergy to azole agents or zinc. Women with non-albicans Candida species will be excluded from the final data analysis.
Sites / Locations
- Dr. Secret Private ClinicRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
JUVIA zinc-containing vaginal gel and Fluconazole
Fluconazole
JUVIA zinc containing vaginal gel group. Receive oral fluconazole treatment (150 mg) and after that participants will use a zinc containing- vaginal gel for 12 weeks.
Control group. Receive oral fluconazole treatment.